Evidence map›Paper›PMID 41876446›Full record

ArticleCell death & disease2026

The ATC12 small molecule inhibits the Aurora-A/TPX2 interaction and impairs the proliferation of breast cancer cells.

Dalila Boi, Giulia Fianco, Federica Polverino, Francesco Fiorentino, Anna Mastrangelo, Simone Rossi, Elisabetta Rubini, Serena Rosignoli, Francesca Troilo, Maria Rosaria Antonelli and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Dalila Boi *Institute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Giulia Fianco *Institute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Federica PolverinoInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Francesco FiorentinoDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0003-3550-1860
Anna MastrangeloInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Simone RossiDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0009-0006-2869-5627
Elisabetta RubiniDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.
Serena RosignoliCentre for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID http://orcid.org/0000-0002-0164-8998
Francesca TroiloInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Maria Rosaria AntonelliInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Dalila TarquiniInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.
Laura CervoniDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.
Serena RinaldoDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0003-0682-023X
Angela TramontiInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-5625-1170
Eleonora Kristina ScarponeGSTeP-Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome, Italy.
Chiara NaroGSTeP-Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome, Italy.
Claudio SetteGSTeP-Organoids Research Core Facility, IRCCS Fondazione Policlinico A. Gemelli, Rome, Italy.ORCID http://orcid.org/0000-0003-2864-8266
Venturina StagniInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-3971-0398
Gianni ColottiInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-9913-0635
Dante RotiliDepartment of Science, Roma Tre University, Rome, Italy.
Alessandro PaiardiniDepartment of Biochemical Sciences, Sapienza University of Rome, Rome, Italy. alessandro.paiardini@uniroma1.it.ORCID http://orcid.org/0000-0001-9078-7545
Giulia GuarguagliniInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy. giulia.guarguaglini@uniroma1.it.ORCID http://orcid.org/0000-0002-7541-8183
Italia Anna AsteritiInstitute of Molecular Biology and Pathology, National Research Council of Italy, c/o Sapienza University of Rome, Rome, Italy. italiaanna.asteriti@cnr.it.ORCID http://orcid.org/0000-0002-6582-5500

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) ID 29699-2023 post-doctoral fellowshipAssociazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG-2021 ID: 25648Consiglio Nazionale delle Ricerche (National Research Council) laboratori congiunti internazionali del CNR (Scienze biomediche 2024-2026) CUP: B53C23007690001Regione Lazio (Region of Lazio) PROGETTI DI GRUPPI DI RICERCA 2020 project ID: A0375-2020-36597Sapienza Università di Roma (Sapienza University of Rome) ADD SAPIExcellence 2024 Fellowship
6 · The paper itself

Abstract

The Aurora-A kinase and its major regulator TPX2 act as key players during mitosis. Both are overexpressed in tumors, and the Aurora-A/TPX2 complex has been proposed as a potential oncogenic holoenzyme. Evidence of Aurora-A non-mitotic roles in cancer, some of which depend on its nuclear accumulation in interphase and are independent from the kinase activity, is emerging. Indeed, many Aurora-A ATP-competitive inhibitors have shown limited efficacy in clinical trials so far, highlighting the need for novel strategies to inhibit Aurora-A. Interestingly, our recent results suggest an involvement of TPX2 also in the non-mitotic protumorigenic roles of Aurora-A, which makes the Aurora-A/TPX2 complex a promising target. We previously described Aurora-A/TPX2 protein-protein interaction inhibitors. Here, starting from in silico analyses, we identified a new compound, i.e., ATC12, which we validated in vitro as a molecule able to bind Aurora-A and to compete with TPX2. We investigated the effects of ATC12 in 2D cultures and 3D mammospheres of breast cancer cell lines, as well as in patient-derived organoids, and observed an impairment of Aurora-A/TPX2 interaction and a decrease in cell viability and proliferation. Altogether, our observations support the targeting of the Aurora-A/TPX2 complex as a promising strategy for the development of novel anti-cancer therapeutics.

Indexed as

Aurora Kinase ABreast NeoplasmsCell Cycle ProteinsMicrotubule-Associated ProteinsNuclear ProteinsSmall Molecule LibrariesCell Line, TumorCell ProliferationFemaleHumansProtein BindingAURKA protein, humanAurora Kinase ACell Cycle ProteinsMicrotubule-Associated ProteinsNuclear ProteinsSmall Molecule LibrariesTPX2 protein, human

Identifiers

PMID41876446
PMCPMC13039486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.